Status:

COMPLETED

National Fully Remote Use of IpsiHand Device in Hemiparetic Stroke

Lead Sponsor:

Neurolutions, Inc.

Collaborating Sponsors:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Conditions:

Stroke

Hemiparesis

Eligibility:

All Genders

18-85 years

Phase:

NA

Brief Summary

The goal of this study is to define the efficacy of fully remote home-based BCI therapy in chronic hemiparetic subcortical stroke patients. A randomized controlled study using the integrated remote BC...

Detailed Description

The ultimate goal of this project is to develop a functioning and clinically feasible method for restoring function to motor impaired stroke survivors. This ultimate goal is to develop a system that a...

Eligibility Criteria

Inclusion

  • Adults age (18-85)
  • Adults who sustained a CVA
  • Have upper extremity hemiparesis/hemiplegia
  • Participants who are not receiving Botox Injections for the upper extremity may be included. Should a participant be receiving Botox injections for the upper extremity, they may be included but Botox administration must be timed to coincide within a week of the beginning of training.

Exclusion

  • Participants who are not receiving Botox Injections for the upper extremity may be included. Should a participant be receiving Botox injections for the upper extremity, they may be included but Botox administration must be timed to coincide within a week of the beginning of training.
  • Participants who are too cognitively impaired to understand the task or provide informed consent will be excluded. A Short-Blessed Test score of 8 or more will be excluded.
  • Participants who have contractures in the affected wrist and digits will be excluded, as the device will not comfortably fit.
  • Participants who have receptive aphasia and unable to follow written directions will be excluded. A score of 6 or less on the MS Aphasia Screening Test will be excluded.
  • Participants receiving any formal upper extremity therapy will be excluded.
  • Participants with ataxia apraxia or severe psychiatric illness (other than post stroke depression) will be excluded.
  • Participants who are pregnant or breast-feeding will be excluded.
  • Participants who have nerve or sensory impairment that may limit or interfere with their ability to sense pain will be excluded.

Key Trial Info

Start Date :

October 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 30 2025

Estimated Enrollment :

109 Patients enrolled

Trial Details

Trial ID

NCT05965713

Start Date

October 1 2023

End Date

October 30 2025

Last Update

December 15 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Washington University in Saint Louis

St Louis, Missouri, United States, 63110